Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India.

Trial Profile

Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2021.
    • 31 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2019.
    • 01 Dec 2015 Results published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top